Last10K.com

Spring Bank Pharmaceuticals, Inc. (SBPH) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Spring Bank Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1566373 Ticker: SBPH
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Mar. 07, 2019
Jun. 29, 2018
Document And Entity Information [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2018  
Document Fiscal Year Focus2018  
Document Fiscal Period FocusFY  
Trading Symbolsbph  
Entity Registrant NameSpring Bank Pharmaceuticals, Inc.  
Entity Central Index Key0001566373  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Filer CategoryAccelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companytrue  
Entity Ex Transition Periodtrue  
Entity Shell Companyfalse  
Entity Public Float  $ 128.9
Entity Common Stock, Shares Outstanding 16,436,895 

View differences made from one year to another to evaluate Spring Bank Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Spring Bank Pharmaceuticals, Inc..

Continue

Assess how Spring Bank Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Spring Bank Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity
Consolidated Statements Of Changes In Stockholders' Equity (Parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
401(K) Plan
401(K) Plan - Additional Information (Detail)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (Tables)
Accrued Expenses And Other Current Liabilities - Schedule Of Accrued Expenses (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Summary Of Future Minimum Lease Payments For Operating Leases (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Summary Of Assets And Liabilities Measured At Fair Value (Detail)
Fair Value Measurements - Summary Of Change In Company's Level 3 Liabilities, Warrants Issued In A Private Placement (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Reconciliation Of The Statutory Federal Tax Rate To The Company's Effective Tax Rate (Detail)
Income Taxes - Schedule Of Significant Components Of The Company's Deferred Tax Assets (Detail)
Investments
Investments (Tables)
Investments - Schedule Of Amortized Cost And Fair Value Of Available-For-Sale Investments, By Contract Maturity (Detail)
Investments - Summary Of Available-For-Sale Classified Investments (Detail)
Investments - Summary Of Investments By Category (Detail)
Nature Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies
Nature Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Nature Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Nature Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies - Additional Information (Detail)
Nature Of Business, Basis Of Presentation And Summary Of Significant Accounting Policies - Summary Of Estimated Useful Lives Of Property And Equipment (Detail)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Additional Information (Detail)
Net Loss Per Share - Summary Of Computation Of Basic And Diluted Net Loss Per Share (Detail)
Net Loss Per Share - Summary Of Potentially Dilutive Securities Outstanding Excluded From Computation Of Diluted Weighted-Average Shares Outstanding (Detail)
Property And Equipment, Net
Property And Equipment, Net (Tables)
Property And Equipment, Net - Additional Information (Detail)
Property And Equipment, Net - Schedule Of Property And Equipment (Detail)
Related Party Transactions
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity - Additional Information (Detail)
Stockholders' Equity - Summary Of Assumptions To Determine Fair Value Of Stock Options Granted (Detail)
Stockholders' Equity - Summary Of Assumptions Used To Record Fair Value Of Warrants (Detail)
Stockholders' Equity - Summary Of Option Activity (Detail)
Stockholders' Equity - Summary Of Shares Of Common Stock Reserved (Detail)
Stockholders' Equity - Summary Of Stock-Based Compensation Expense (Detail)
Stockholders' Equity - Summary Of Warrant Activity (Detail)
Subsequent Events
Ticker: SBPH
CIK: 1566373
Form Type: 10-K Annual Report
Accession Number: 0001564590-19-007078
Submitted to the SEC: Mon Mar 11 2019 6:06:57 AM EST
Accepted by the SEC: Mon Mar 11 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/sbph/0001564590-19-007078.htm